SCHEMBL4427092

SCHEMBL4427092

O=P(O)(O)CNS(=O)(=O)c1ccccn1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
KAT6A Q92794 1/20 0.51
FDPS P14324 4/20 0.45
GLO1 Q04760 3/20 0.42
SLC40A1 Q9NP59 2/20 0.42
METAP2 P50579 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
LOX P28300 1/20 0.39
PTGS2 P35354 1/20 0.39
MMP2 P08253 1/20 0.39
NLRP3 Q96P20 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
CTSK P43235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4424427 0.77 L3MBTL1 (0.44) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL18881310 0.76 L3MBTL1 (0.65) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL17372076 0.76 L3MBTL1 (0.65) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL10438614 0.75 KAT6A (0.63) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL7386558 0.74 L3MBTL1 (0.54) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL12000989 0.73 L3MBTL1 (0.56) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL6905652 0.73 L3MBTL1 (0.46) L3MBTL1KAT6AGLO1SLC40A1KDM4E
SCHEMBL17489126 0.73 L3MBTL1 (0.59) L3MBTL1KAT6AGLO1SLC40A1METAP2
SCHEMBL4257915 0.72 L3MBTL1 (0.59) L3MBTL1KAT6AGLO1SLC40A1KDM4E
SCHEMBL5152771 0.72 L3MBTL1 (0.59) L3MBTL1KAT6AGLO1SLC40A1METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514556-B2 Inhibitors of β-lactamase METHYLGENE INC. (CA) 2009-04-07 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-20060105999-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2006-05-18 US disclosed
US-7030103-B2 Sulfonamidomethyl phosphonate inhibitors of β-lactamase METHYLGENE, INC. (CA) 2006-04-18 US disclosed
EP-1194436-B1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2005-11-30 EP disclosed
US-6921756-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-07-26 US disclosed
US-6884791-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-04-26 US disclosed
US-20050043276-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2005-02-24 US disclosed
WO-2004048393-A2 NOVEL INHIBITORS OF β-LACTAMASE METHYLGENE, INC. (CA) 2004-06-10 WO disclosed
US-20040082546-A1 Novel Inhibitors of beta-lactamase METHYLGENE, INC. 2004-04-29 US disclosed
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-03-25 US disclosed
US-20040029836-A1 Novel inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-02-12 US disclosed
US-6472406-B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2002-10-29 US disclosed
EP-1194436-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE Methylgene, Inc. (CA) 2002-04-10 EP disclosed
WO-2001002411-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE METHYLGENE INC. (CA) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043276-A1 Novel inhibitors of beta-lactamase MGAM, LSS, CYP51A1 L3MBTL1 1302/4885KAT6A 3840/4885FDPS 116/4885
US-20040029836-A1 Novel inhibitors of beta-lactamase LSS, MGAM, COASY L3MBTL1 1385/4885KAT6A 3742/4885FDPS 116/4885
US-20060105999-A1 Novel inhibitors of beta-lactamase LSS, MGAM, LCT L3MBTL1 1338/4885KAT6A 3660/4885FDPS 128/4885
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase PGLS, MGAM, STS L3MBTL1 1328/4885KAT6A 2677/4885FDPS 110/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 L3MBTL1 1302/4885KAT6A 3840/4885FDPS 116/4885
US-20040082546-A1 Novel Inhibitors of beta-lactamase LSS, MGAM, COASY L3MBTL1 1305/4885KAT6A 3615/4885FDPS 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.